Abstract
Pychoeducation is a useful and required intervention in subjects with elevated-risk state of psychosis. Psychoeducation is, however, an under-investigated area in the field of early identification and prevention. Psychoeducation with this particular patient group needs to adapt to several unique features, e.g. the diagnostic uncertainty (“say it only in subjunctive”) and problems of stigmatization. More research regarding the subjective psychoeducational needs of individuals at elevated risk for psychosis as well as more explicit provision and evaluation of psychoeducation in the elevated-risk state is strongly desirable.
Keywords: Psychoeducation, psychotherapy, schizophrenia, ultra-high risk, stigmatization, clinical stability, social interaction, quality of life, symptoms, pilot data
Current Pharmaceutical Design
Title: Psychoeducation in Subjects at Elevated Risk for Psychosis - A Critical Review
Volume: 18 Issue: 4
Author(s): Marta Hauser and Georg Juckel
Affiliation:
Keywords: Psychoeducation, psychotherapy, schizophrenia, ultra-high risk, stigmatization, clinical stability, social interaction, quality of life, symptoms, pilot data
Abstract: Pychoeducation is a useful and required intervention in subjects with elevated-risk state of psychosis. Psychoeducation is, however, an under-investigated area in the field of early identification and prevention. Psychoeducation with this particular patient group needs to adapt to several unique features, e.g. the diagnostic uncertainty (“say it only in subjunctive”) and problems of stigmatization. More research regarding the subjective psychoeducational needs of individuals at elevated risk for psychosis as well as more explicit provision and evaluation of psychoeducation in the elevated-risk state is strongly desirable.
Export Options
About this article
Cite this article as:
Hauser Marta and Juckel Georg, Psychoeducation in Subjects at Elevated Risk for Psychosis - A Critical Review, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316127
DOI https://dx.doi.org/10.2174/138161212799316127 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Limitations in the Treatment of Parkinson’s and Alzheimer’s Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers
Current Medicinal Chemistry The Immune System and the Brain: Crosstalk with a Broad Impact From Host Defense to Cognition
Current Neurovascular Research Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth
Current Medicinal Chemistry The SCF-type E3 Ubiquitin Ligases as Cancer Targets
Current Cancer Drug Targets Synthesis and Reactions of Perimidines and Their Fused Systems
Current Organic Chemistry Anti-Epidermal Growth Factor Receptor Strategies to Enhance Radiation Action
Current Medicinal Chemistry - Anti-Cancer Agents Polymorphism of UDP-Glucuronosyltransferase and Drug Metabolism
Current Drug Metabolism Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder
Current Neuropharmacology Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Redox Environment and its Meaning for Breast Cancer Cells Fate
Current Cancer Drug Targets DNA Vaccination in Oncology: Current Status, Opportunities and Perspectives
Current Clinical Pharmacology A Potential Anticancer Agent 1,2-di(quinazolin-4-yl)diselane
Letters in Drug Design & Discovery MicroRNA-203: Tumor Suppression and Beyond
MicroRNA The Importance of Melatonin and Mitochondria Interaction in Mood Disorders and Schizophrenia: A Current Assessment
Current Medicinal Chemistry Inflammatory Cytokines, Growth Factors, and Depression
Current Pharmaceutical Design Selected Attributes of Polyphenols in Targeting Oxidative Stress in Cancer
Current Topics in Medicinal Chemistry Angiogenesis and Vascularization of Uterine Leiomyoma: Clinical Value of Pseudocapsule Containing Peptides and Neurotransmitters
Current Protein & Peptide Science Immunomics in Skin Cancer - Improvement in Diagnosis, Prognosis and Therapy Monitoring
Current Proteomics Recent Advances in Targeted Therapy for Glioma
Current Medicinal Chemistry